Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD30 CAR T cells HSP-CAR30

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the CD30 antigen, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD30 CAR T cells HSP-CAR30 specifically recognize and bind to CD30-expressing tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CD30-targeting CAR T cells HSP-CAR30
Code name:HSP CAR30
HSP-CAR30
HSPCAR30
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search